Skip to main content

Table 1 Baseline demographic factors, cardiovascular disease risk factors, and laboratory measurements in 330 participants

From: Associations of serum and dialysate electrolytes with QT interval and prolongation in incident hemodialysis: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study

Variables

Mean (± SD), median (IQR), frequency (%)

Demographic factors

 Age, years

54.6 (± 13.3)

 Sex

  Male

206 (62.4)

  Female

124 (37.6)

 Ethnicity

  Non-African American

87 (26.4)

  African American

243 (73.6)

Physical information

 Body mass index, kg/m2

27.8 (23.5, 33.3)

 Non-dialysis study visit systolic, mmHg

137.8 (± 25.3)

 Non-dialysis study visit diastolic, mmHg

75.0 (± 14.7)

 Non-dialysis study visit pulse pressure, mmHg

62.8 (± 18.1)

Comorbidities

 Hypertension

330 (100.0)

 Hypercholesterolemia

228 (69.1)

 Diabetes

187 (56.7)

 Coronary artery disease

116 (35.2)

 Charlson comorbidity index

5 (4, 6)

Medications

 Total number of antihypertensive medications

2.7 (± 1.3)

 Beta-blocker

207 (69.5)

 RAASa blockade

127 (42.6)

 Calcium channel blockers

183 (61.4)

 Alpha blockers

32 (10.7)

 Vasodilators

102 (34.2)

 Diuretic

68 (22.8)

 Cinacalcet

15 (5.0)

 QT prolonging medicationb

118 (35.8)

Cardiac parameters

 Left ventricular mass index, g/m2.7

61.3 (50.1, 80.4)

 Left ventricular ejection fraction, %

65.5 (± 11.9)

Laboratory measurements

 3-month average hemoglobin, g/dl

10.8 (± 1.2)

 pH

7.34 (± 0.04)

Laboratory measurements

 Total calciumc, mg/dl

8.8 (± 0.6)

 Corrected calciumc, mg/dl

9.0 (± 0.6)

 Ionized calciumd, mmol/l

1.15 (± 0.07)

 Total potassiumc, mEq/l

4.4 (± 0.6)

 Magnesiumd, mEq/l

1.76 (± 0.24)

Dialysate measurements

 Calciumc, mEq/l

  2

139 (42.1)

  2.25

14 (4.2)

  2.5

174 (52.7)

  3

3 (0.9)

 Potassiumc, mEq/l

  1

5 (1.5)

  2

278 (84.2)

  3

47 (14.2)

Serum-dialysate measurements

 Total calciumc, mEq/l

2.1 (± 0.4)

 Corrected calciumc, mEq/l

2.2 (± 0.4)

ECG measurements

 QT intervald, ms

436.0 (± 55.6)

 Corrected QT intervald, ms

455.4 (± 46.0)

 QT prolongationd

155 (47.0)

  1. aRenin-angiotensin-aldosterone system blockade includes angiotensin-converting-enzyme inhibitor and angiotensin II receptor blocker
  2. bListed in Additional file 1: Table S1
  3. cMeasurement closest to the study clinic visit
  4. dNon-dialysis (interdialytic) measurements